A leading Korean contract research organization (CRO) called LSK Global Pharma Services will conduct the Phase 3 clinical trial of Sinovac’s COVID-19 vaccine candidate in Bangladesh. Targeting approximately 4,200 frontline health workers at seven Dhaka-based hospitals, this important vaccine trial centers on the nation in Asia with the second-highest number of COVID-19 cases—as of this writing it's 317,528.
Just a week ago, Bangladesh authorities approved the late-stage clinical trial sponsored by China’s Sinovac Biotech Ltd in a bid to be at the top of the list for the vaccine, reported Reuters. Already state medical research authorities had signed off a month previous. Bangladesh has been considering Indian vaccines as well due to the severity of the epidemic.
Heavily Population Centers
Sinovac is signing up large, heavily populated nations for Phase 3 clinical trials as the number of coronavirus cases in China continues downward. Meanwhile, Sinovac signed up Indonesia (268m) and Brazil (210m) and, of course, now Bangladesh (161m).
Busy Trial Sites
The hospitals selected as trial sites in the nation’s most populated city, Dhak (21m inhabitants), are t...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).